View abstract

This abstract is assigned to session BOG-SBO 6 Glaucoma / Glaucome

Title	Intravitreal triamcilonone acetonide : additional treatment of the neovascular glaucoma
Abstract Nr.	A2052

Purpose	To report the clinical outcome of patients who received an intravitreal injection of crystalline triamcinolone acetonide (Kenacort®) as treatment of neovascular glaucoma.
Methods	The study included prospectively 10 eyes of 9 patients with secondary neovascular glaucoma due to proliferative diabetic retinopathy (n = 3) or central retinal vein occlusion (n = 3) or central retinal artery occlusion (n = 3) or panuveitis (n =1). All patients received an intravitreal injection of 20 mg of crystalline triamcinolone acetonide (0.1cc) as the only procedure (n = 4) or in combination with additional procedures, such as transscleral peripheral retinal cryocoagulation (n = 2) or transscleral diode laser of the ciliary bodies (n = 6). Mean intraocular pressure (IOP) was 28.6 ± 20 mmHg.
Results	After surgery, patients reported no ocular pain as compared to pain due to "neurotrophic keratitis" sometimes observed after diode laser of the ciliary bodies alone. Furthermore no ocular inflammatory reaction was observed during the follow-up. Intraocular pressure was significantly reduced to 14 ± 12 mm Hg at the end of the follow-up period. When considering only the 4 patients for whom the intraocular cortisone injection was the only procedure performed, mean intraocular pressure decreased from 32.25 mm Hg to 19.5 mm Hg.
Conclusion	Intravitreal triamcinolone acetonide appears to have an anti-angiogenic effect and may represent an useful additional tool in the patient outcome and in treatment of neovascular glaucoma. There are, however, limitations to the present study : Does the intravitreal triamcinolone chronically control the disease ?

Author 1

Last name	CROMMEN
Initials	J
Department	CHU
City	Liège

Author 2

Last name	RAKIC
Initials	J-M
Department	CHU
City	Liège

Author 3

Last name	COLLIGNON
Initials	N
Department	CHU
City	Liège